MA28609B1 - Vaccins - Google Patents

Vaccins

Info

Publication number
MA28609B1
MA28609B1 MA29491A MA29491A MA28609B1 MA 28609 B1 MA28609 B1 MA 28609B1 MA 29491 A MA29491 A MA 29491A MA 29491 A MA29491 A MA 29491A MA 28609 B1 MA28609 B1 MA 28609B1
Authority
MA
Morocco
Prior art keywords
vaccines
Prior art date
Application number
MA29491A
Other languages
English (en)
Inventor
Patrick Chomez
Catherine Pascaline Anne Ghislaine Collignon
Mechelen Marcelle Paulette Van
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of MA28609B1 publication Critical patent/MA28609B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA29491A 2004-05-21 2006-11-28 Vaccins MA28609B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0411411.2A GB0411411D0 (en) 2004-05-21 2004-05-21 Vaccines

Publications (1)

Publication Number Publication Date
MA28609B1 true MA28609B1 (fr) 2007-05-02

Family

ID=32607764

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29491A MA28609B1 (fr) 2004-05-21 2006-11-28 Vaccins

Country Status (16)

Country Link
US (1) US20080069832A1 (fr)
EP (1) EP1761275A2 (fr)
JP (1) JP2007538044A (fr)
KR (1) KR20070029730A (fr)
CN (1) CN1956729A (fr)
AU (1) AU2005244615A1 (fr)
BR (1) BRPI0511185A (fr)
CA (1) CA2564778A1 (fr)
GB (1) GB0411411D0 (fr)
IL (1) IL178890A0 (fr)
MA (1) MA28609B1 (fr)
MX (1) MXPA06013386A (fr)
NO (1) NO20065304L (fr)
RU (1) RU2006139424A (fr)
WO (1) WO2005112991A2 (fr)
ZA (1) ZA200609500B (fr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0609547A2 (pt) 2005-03-31 2011-10-18 Glaxosmithkline Biolog Sa composição, uso de uma composição, método para o tratamento ou prevenção de infecção por chlamydia, uso de uma ou mais proteìnas de chlamydia, de fragmentos imunogênicos das mesmas ou de polinucleotìdeos codificando os mesmos, método para o tratamento ou prevenção de infecção por chlamydia, e, método para a determinação prévia de infecção por chlamydia em um indivìduo
SI2457926T1 (sl) 2005-04-29 2015-01-30 Glaxosmithkline Biologicals S.A. Nov postopek za preprečevanje ali zdravljenje infekcije z M. tuberculosis
MX2007014390A (es) * 2005-05-19 2008-02-12 Glaxosmithkline Biolog Sa Composicion de vacuna que comprende subunidad b de termo toxina e. coli y antigeno y adyuvante.
GB0524409D0 (en) * 2005-11-30 2006-01-11 Glaxosmithkline Biolog Sa Vaccines
GB0524408D0 (en) * 2005-11-30 2006-01-11 Glaxosmithkline Biolog Sa Vaccines
EP2013227A4 (fr) * 2006-05-09 2010-07-28 Jackson H M Found Military Med Compositions immunogènes anti-vih-1
EP1938836A1 (fr) * 2006-12-28 2008-07-02 Universite Rene Descartes (Paris V) Compositions comprenant une sous-unité B de la toxine dysentérique et moyen de stimulation des cellules NKT
KR101238795B1 (ko) 2007-05-24 2013-03-07 글락소스미스클라인 바이오로지칼즈 에스.에이. 동결건조 항원 조성물
GB0724357D0 (en) * 2007-12-14 2008-01-23 Glaxosmithkline Biolog Sa Method for preparing protein conjugates
WO2009126819A1 (fr) 2008-04-09 2009-10-15 Advanced Immune Therapeutics, Inc. Procédé pour améliorer la bioactivité d'anticorps d'ige thérapeutiques, pour le traitement d'une maladie
JP2012523379A (ja) * 2009-04-09 2012-10-04 ザ ユニバーシティー オブ メルボルン 免疫原性組成物およびその使用
AU2009344150B2 (en) * 2009-04-09 2014-10-09 Innavac Pty Ltd Immunogenic composition and uses thereof
GB0910045D0 (en) * 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
GB0910046D0 (en) * 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
AR077636A1 (es) 2009-07-08 2011-09-14 Abbott Biologicals Bv Vacuna viral y uso de la misma
EP2506834B1 (fr) 2009-12-03 2016-03-02 Novartis AG Circulation de constituants lors de l'homogénéisation et de la microfluidisation d'émulsions
DE102009056884B4 (de) 2009-12-03 2021-03-18 Novartis Ag Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben
CL2012001399A1 (es) * 2009-12-03 2013-03-08 Novartis Ag Metodo para fabricar adyuvante para vacuna (emulsion aceite/agua con escualeno, polisorbato 80 y trioleato de sorbitan), que comprende (i) formar primera emulsion en homogenizador desde un contendor a otro para formar segunda emulsion, (ii) y microfluidizar primera emulsion para formar segunda emulsion.
DK2343052T3 (da) 2009-12-03 2013-09-02 Novartis Ag Hydrofil filtrering under fremstilling af vaccineadjuvanter
DE102009056883B4 (de) * 2009-12-03 2012-08-16 Novartis Ag Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben
WO2012037612A1 (fr) 2010-09-22 2012-03-29 The University Of Melbourne Nouvelle méthode d'immunostimulation
DK2651436T3 (da) 2010-12-14 2016-06-20 Glaxosmithkline Biologicals Sa Mycobakterie antigen sammensætning.
CN102161998B (zh) * 2011-01-14 2013-01-09 中国人民解放军军事医学科学院附属医院 基于b7-1-pe40kdel外毒素融合基因的dna疫苗及其用途
GB201106357D0 (en) 2011-04-14 2011-06-01 Pessi Antonello Composition and uses thereof
EP2734539A1 (fr) * 2011-07-22 2014-05-28 GlaxoSmithKline Biologicals S.A. Purification de prame
EP2666785A1 (fr) 2012-05-23 2013-11-27 Affiris AG Vaccins basés sur la protéine complément C5a
EP2703483A1 (fr) 2012-08-29 2014-03-05 Affiris AG Vaccin à base de PCSK9
JP5931113B2 (ja) * 2014-04-08 2016-06-08 ザ ユニバーシティー オブ メルボルン 免疫原性組成物およびその使用
TW201623329A (zh) 2014-06-30 2016-07-01 亞佛瑞司股份有限公司 針對骨調素截斷變異體的疫苗及單株抗體暨其用途
EP3551222B1 (fr) * 2016-12-07 2024-08-07 GlaxoSmithKline Biologicals SA Procede de fabrication d'une composition de liposome comprenant une saponine
GB201621686D0 (en) * 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
KR101966346B1 (ko) * 2017-01-13 2019-04-05 전북대학교 산학협력단 시가 독소 Stx2e를 제조하는 방법 및 이를 포함하는 부종병을 예방하기 위한 백신 조성물
KR101987851B1 (ko) 2017-04-28 2019-06-11 한국생명공학연구원 장출혈성대장균 유래의 시가독소 타입 1 B-subunit으로 유도된 노인성 황반변성(AMD) 동물모델 및 이를 이용한 스크리닝 방법
WO2018220553A1 (fr) 2017-05-30 2018-12-06 Glaxosmithkline Biologicals Sa Procédés de fabrication d'un arn encapsulé dans un liposome
PL3728289T3 (pl) 2017-12-21 2026-01-26 Axelia Oncology Pty Ltd Zoptymalizowane związki
CN108992667A (zh) * 2018-08-09 2018-12-14 安徽智飞龙科马生物制药有限公司 一种带状疱疹疫苗及其制备方法、应用
WO2020109365A1 (fr) * 2018-11-29 2020-06-04 Glaxosmithkline Biologicals Sa Procédés de fabrication d'un adjuvant
EP3669890A1 (fr) 2018-12-18 2020-06-24 Croda International PLC Nanoparticules filamenteuses ayant un effet d'adjuvant de vaccin
JP2022539091A (ja) 2019-06-26 2022-09-07 アクセリア オンコロジー ピーティーワイ リミテッド 新規な分子
EP4021407A1 (fr) 2019-08-30 2022-07-06 GlaxoSmithKline Biologicals S.A. Procédé de fabrication de nanoparticules lipidiques mélangées par jet
CN111333734B (zh) * 2020-03-31 2022-05-03 中国人民解放军军事科学院军事医学研究院 一种百日咳丝状血凝素融合蛋白及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2138997C (fr) * 1992-06-25 2003-06-03 Jean-Paul Prieels Composition vaccinale qui contient des adjuvants
EP0817647A4 (fr) * 1995-03-24 2002-10-30 Promega Corp Traitement contre escherichia coli producteur de verotoxines
GB9711990D0 (en) * 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
DE69928523T2 (de) * 1998-05-15 2006-08-10 Institut Curie Verotoxin b untereinheit zur immunisierunug
CN1227030C (zh) * 1999-04-19 2005-11-16 史密丝克莱恩比彻姆生物有限公司 包含皂甙和免疫刺激寡核苷酸的佐剂组合物
EP1229045A1 (fr) * 2001-02-01 2002-08-07 Institut Curie Support universel pour le ciblage de molécules sur des cellules exprimant le récepteur Gb3

Also Published As

Publication number Publication date
KR20070029730A (ko) 2007-03-14
CA2564778A1 (fr) 2005-12-01
WO2005112991A3 (fr) 2006-03-30
JP2007538044A (ja) 2007-12-27
EP1761275A2 (fr) 2007-03-14
WO2005112991A2 (fr) 2005-12-01
RU2006139424A (ru) 2008-06-27
US20080069832A1 (en) 2008-03-20
BRPI0511185A (pt) 2007-12-04
CN1956729A (zh) 2007-05-02
GB0411411D0 (en) 2004-06-23
IL178890A0 (en) 2007-03-08
ZA200609500B (en) 2008-02-27
MXPA06013386A (es) 2007-01-23
NO20065304L (no) 2006-11-20
AU2005244615A1 (en) 2005-12-01

Similar Documents

Publication Publication Date Title
HUS2200002I1 (hu) Immunogén készítmény
MA28885B1 (fr) vaccins
DK1959991T3 (da) Terapeutisk vaccine
DK1968631T3 (da) Vaccine
TWI365191B (en) Vaccine
ATE462445T1 (de) Prrs-impfstoffe
IL178890A0 (en) Vaccines
GB0922611D0 (en) Improved vaccines
MA28639B1 (fr) Vaccins
EP1678292A4 (fr) Vaccins mva ameliores
EP1732597A4 (fr) Vaccin contre streptococcus agalactiae
EP1660636A4 (fr) Vaccins anticancer
EP2061502A4 (fr) Vaccin
GB0411150D0 (en) Vaccine
EP1807116A4 (fr) Vaccination antigrippale
EP1872794A4 (fr) Vaccin nasal
IS8325A (is) Bóluefni
GB0413510D0 (en) Vaccine
EP1948782A4 (fr) Adjuvants de vaccins
GB0524408D0 (en) Vaccines
GB0412407D0 (en) Vaccine
GB0428381D0 (en) Vaccine
GB0419918D0 (en) Vaccine
GB0406598D0 (en) Vaccine
AP2709A (en) An anti-theileriosis vaccine